# Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)

> **NCT04760730** · PHASE1,PHASE2 · COMPLETED · sponsor: **R-Pharm** · enrollment: 100 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** AZD1222
- **BIOLOGICAL:** rAd26-S

## Key facts

- **NCT ID:** NCT04760730
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-13
- **Primary completion:** 2022-03-29
- **Final completion:** 2022-07-26
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04760730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04760730, "Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04760730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*